Kornimate/medical-research-clean huggingface dataset:
dietary factors and disfluency: a look into food allergies and other environmental triggers associated with variations in severity of vocal cord tension.

Conditions: Vocal Cord Tension; Dysfluency Developmental

Summary: the purpose of this study is to see whether participants with persistent developmental disfluency who report fluctuational disfluency due to vocal cord tension on a day to day basis of can achieve a more normalized fluency by identifying dietary allergen responses and subsequently eliminating these dietary triggers from their daily consumption.


Eligibility criteria:
inclusion criteria: * patients reporting persistent developmental disfluency. exclusion criteria: * patients reporting no changes in disfluency severity or frequency
total neoadjuvant therapy in rectal cancer treatment

Conditions: Rectal Cancer

Summary: this is a randomized, controlled, parallel study to determine the efficiency and safety of total neoadjuvant therapy in rectal cancer treatment.

in this randomized, controlled, parallel study we will comparison total neoadjuvant therapy with standard neoadjuvant therapy in rectal cancer treatment. complete pathological response rate will be the primary endpoint in patients, who will undergoing surgery. in cases of complete clinical response we will provide "watch and wait" approach. compliance of treatment and oncologic results will be the second endpoint.

Eligibility criteria:
inclusion criteria: * have signed an approved informed consent form for the stud; * histologically confirmed rectal adenocarcinoma low (ct2-4n0-2m0) or mid rectum (ст2-t4n1-2m0); exclusion criteria: * rectal cancer recurrence; * primary-multiple tumours of other localizations; * pelvis radiotherapy in anamnesis; * pregnancy, breastfeeding; * distant metastasis; * ecog score 3-4

Keywords: rectal cancer total neoadjuvant therapy colorectal disease
myocarditis causing premature ventricular contractions:insights from the maveric registry

Conditions: Myocarditis; Premature Ventricular Contractions; Ventricular Tachycardia (VT)

Summary: to assess potential link between unrecognized myocardial inflammation (myocarditis) and premature ventricular contractions (pvcs) associated with and without reduced left ventricular ejection fraction (lvef) through comprehensive diagnostic work up.

hypothesized that occult inflammation is clinically under-recognized in patients with symptomatic pvcs with and without left ventricular (lv) dysfunction and can be a potential link between the 2 conditions. aimed to evaluate the incidence of underlying inflammation using the positron emission tomography (pet) scan in patients presenting with symptomatic pvcs enrolled retrospectively in the maveric registry.

Eligibility criteria:
inclusion criteria: * patients \> 18 years of age with mono-morphic or polymorphic pvc burden of ≥5000 in 24 hours. * non-sustained vt was defined as ≥3 more consecutive beats lasting \<30 seconds exclusion criteria: * history of myocardial infarction, * significant flow-limiting coronary artery disease (≥50% stenosis) on invasive coronary angiography or ct angiography, * history of revascularization, * significant symptomatic atrial arrhythmias associated with lv dysfunction, * severe valvular disease, * cardiomyopathy attributed to toxins such as alcohol and illicit drugs, * history of cardiac arrest, * history of channelopathies or inherited arrhythmias.
a phase iii study of radium-223 dichloride in patients with symptomatic hormone refractory prostate cancer with skeletal metastases

Conditions: Hormone Refractory Prostate Cancer; Bone Metastases

Summary: alsympca (alpharadin in symptomatic prostate cancer) is an international phase iii clinical study to evaluate the efficacy and safety of radium-223 dichloride in patients with hormone refractory prostate cancer and skeletal metastases.

the aim of the study was to compare, in patients with symptomatic hormone refractory prostate cancer (hrpc) and skeletal metastases, the efficacy of best standard of care plus radium-223 dichloride versus best standard of care plus placebo, with the primary efficacy endpoint being overall survival (os). patients were randomised in a 2:1 allocation ratio (radium-223 dichloride:placebo). the study treatment consisted of 6 intravenous administrations of radium-223 dichloride or placebo (saline) each separated by an interval of 4 weeks. the patient were followed until 3 years after first study drug administration. within the u.s., the trial was conducted under an ind sponsored by bayer healthcare pharmaceuticals. all patients received bsoc (best standard of care). this study has the original pcd as 14 october 2010, when a total of 316 deaths had been observed; this resulted in the independent data monitoring committee's (idmc's) recommendation to stop the study as the primary efficacy analysis of overall survival had crossed the pre-specified boundary for efficacy. later an updated analysis of primary endpoint in the first addendum was done with cut-off of 15 july 2011.

Eligibility criteria:
inclusion criteria: * histologically or cytologically confirmed adenocarcinoma of the prostate * known hormone refractory disease * multiple skeletal metastases (≥ 2 hot spots) on bone scintigraphy * no intention to use cytotoxic chemotherapy within the next 6 months * either regular (not occasional) analgesic medication use for cancer related bone pain or treatment with ebrt (external beam radiation therapy) for bone pain exclusion criteria: * treatment with an investigational drug within previous 4 weeks, or planned during the treatment period * eligible for first course of docetaxel, i.e. patients who are fit enough, willing and where docetaxel is available * treatment with cytotoxic chemotherapy within previous 4 weeks, or planned during the treatment period, or failure to recover from adverse events due to cytotoxic chemotherapy administered more than 4 weeks ago * systemic radiotherapy with strontium-89, samarium-153, rhenium-186 or rhenium-188 for the treatment of bony metastases within previous 24 weeks * other malignancy treated within the last 5 years (except non-melanoma skin cancer or low-grade superficial bladder cancer) * history of visceral metastasis, or visceral metastases as assessed by abdominal/pelvic ct or chest x-ray within previous 8 weeks

Keywords: hormone refractory prostate cancer bone metastases radium-223
cipro inhaler for cystic fibrosis children ages 6-12

Conditions: Pseudomonas Infection

Summary: ciprofloxacin pulmosphere inhalation powder appears to be an effective and adequate antibiotic treatment for cystic fibrosis patients with p. aeruginosa colonisation. this planned study is the first study on the use of this new ciprofloxacin pulmosphere inhalation powder in the pediatric population of 6 to 12 years of age.


Eligibility criteria:
inclusion criteria: * male or female patients with cystic fibrosis confirmed by genetic testing and / or by sweat test * colonization with p. aeruginosa confirmed in sputum in the past 12 months * cohort 1: greater than or equal to 18 years of age. * cohort 2: 6 - 12 years of age (inclusive) * normal body mass index: bmi between 14.5 and 30 kg/m2, but in no case lower than the 30th percentile for age. because cf patients are typically smaller than non-cf-patients, the normal body mass index will be based on standard cf foundation normal values for weight and sex. * patients who are able to understand and follow instructions and who are able to participate in the study for the entire period. * patients and legal representatives must have given their written informed consent to participate in the study after receiving adequate previous information and prior to any study specific procedures exclusion criteria: * patients with fev1 \< 35% of predicted. fev1 (forced expiratory volume) is a measure of lung function. this exclusion will prohibit enrollment of patients with severely impaired lung function. * patients with burkholderia cepacia colonization of their respiratory tract * patients with acute bronchopulmonary aspergillosis (abpa) * patients on a lung transplant list * patients with acute pulmonary exacerbations * patients with severe liver cirrhosis * massive hemoptysis in the preceding 4 weeks * a history of relevant diseases of vital organs, of the central nervous system, or other organs not related to the underlying disease * patients with a history of severe allergies, non-allergic drug reactions, or multiple drug allergies * patients with hypersensitivity to the investigational drug or to other quinolones and/ or to inactive constituents * patients with known intolerance to hypertonic saline or bronchodilators * concomitant inhalation therapy with antibiotics and / or concomitant systemic therapy with fluoroquinolones * women who are pregnant

Keywords: cystic fibrosis pharmacokinetics pediatrics inhalation sputum
fu's subcutaneous needling treatment for knee osteoarthritis

Conditions: Knee Osteoarthritis

Summary: the population affected by degenerative knee arthritis is very large. the investigator performed fu's subcutaneous needling (fsn). this experiment used a randomized single-blind experiment to assess the immediate, short-term and long-term effects of fu's subcutaneous needling (fsn) therapy on patellar pain in patients with degenerative arthritis.

the population affected by degenerative knee arthritis is very large. according to a survey conducted by the ministry of health and welfare, the prevalence of osteoarthritis of the knee in taiwan is about 3.5 million people, accounting for about 15% of the total population. its effects are a heavy burden on socio-economic costs, and in addition to being included in medical expenses, serious cases can lead to incapacity to work; therefore, the disease is an important factor in causing disability and disability first, it is worth our attention. floating needle is a kind of dry needle therapy, which has been used in the treatment of degenerative arthritis for more than 20 years. it has been clearly annotated in the treatment strategy that it uses disposable floating needle needles at the superficial subcutaneous fascia, parallel to the muscle to sweep away, and with reperfusion activities, muscle pain caused by muscle fascia and soft tissue pain with immediate and good pain relief effect, but still lack of treatment and rigorous evaluation of the establishment. for the reasons of the degenerative arthritis pain, the clinical observation is not entirely due to the cause of joint deformity or cartilage damage, soft tissue lesions around the knee is also a common source of pain, the use of floating needle for the diagnosis of soft tissue injury , and observed its efficacy, which is also the core of this study. this experiment used a randomized single-blind experiment to assess the immediate, short-term and long-term effects of floating needle therapy on patellar pain in patients with degenerative arthritis. the assessment tools included the vas, womac , lesquesne index, the muscle tension changes in the lower extremities, and gyko .

Eligibility criteria:
inclusion criteria: - 1.volunteers who are older than 50 years old and can cooperate with the experiment. 2.established diagnosis of unilateral or bilateral degenerative knee arthritis. 3.there is a local trigger point around the unilateral or bilateral knee joint which on the muscle of vastus lateralis, vastus medialis, gastrocnemius, or tibialis anterior. exclusion criteria: * 1.there are contraindications to general treatment, such as serious medical problems, recent serious trauma, or pregnant women. 2.there has been a history of drug abuse (including excess alcohol) that affects pain assessors. 3.have received knee surgery. 4.people with central or peripheral nerve disease. 5.cognitive impairment, unable to cooperate with the experimenter. 6.patients currently receiving other treatments for knee osteoarthritis

Keywords: fu's subcutaneous needling myofascial trigger point muscle tone
improvement of fitness in obese children

Conditions: Pediatric Obesity

Summary: this study observes fitness level and health parameters in children ages 6-12 years old with obesity using an exercise class intervention.

the purpose of this study is to improve physical fitness and health parameters in elementary-aged children who participate in an academic weight loss clinic. patients and their parents are randomly assigned to either take exercise classes or to continue standard care (control group). exercise classes are run at a local church 3 times a week for 8 weeks and children and parents are expected to participate. parents are expected to follow similar dietary and exercise recommendations which are given to their children. vitals, lab work and fitness testing are done on children at beginning, middle and end of the 6- month study. vitals are done on parents at the beginning, middle and end of the study. children are given fitbits to record sleep patterns and daily physical activity.

Eligibility criteria:
inclusion criteria: * child must be a patient at the penn state hershey children's hospital pediatric multidisciplinary weight loss program * child must be ages 6-12 years old exclusion criteria: * lack of transportation to exercise classes * parents do not agree to participate in the exercise classes

Keywords: exercise, fitness, sleep, children, obesity
blood characteristics and abdominal emergency surgery

Conditions: Surgical Wound

Summary: after surgical tissue damage, cellular blood components are involved in tissue repair processes, yet their preoperative characteristics are not considered in routine clinical practice.

surgical injuries initiate the recruitment of cellular blood components for tissue repair. baseline inflammation levels and cellular response to tissue damage are absent from perioperative management algorithms despite their importance in regeneration. this project seeks to examine patients preoperative parameters before surgery and evaluate if there is a correlation with clinical outcomes.

Eligibility criteria:
inclusion criteria: * patients between 18 and 65 years of age at surgery. * patients with acute intra-abdominal pathology requiring emergency surgery. * a complete blood count was performed in the emergency department of our center within 24 hours before surgery. exclusion criteria: * patients who are users of anticoagulation before admission for any reason * patients who have had previous hospitalization or surgery in the last 6 months.
evaluation of dipyridamole in preventing post-transplant hypophosphatemia in kidney transplant recipients

Conditions: Hypophosphatemia; Kidney Transplantation

Summary: the primary goal is to determine if dipyridamole can improve serum phosphate levels and reduce the need for phosphate supplementation.


Eligibility criteria:
inclusion criteria: * adult kidney transplant patients. * no known contraindications to dipyridamole exclusion criteria: * contraindications to dipyridamole. * patients with delayed graft function (defined as the need for dialysis within seven days post-transplantation). * patients requiring plavix, direct oral anticoagulants (doacs), or coumadin.

Keywords: post-kidney transplant care dipyridamole renal phosphate loss serum phosphate levels phosphate supplementation transplant graft function kidney transplant complications
a comparison of symbicort® pmdi 2 x 160/4.5 μg bid and symbicort® pmdi 2 x 80/4.5 μg bid with formoterol turbuhaler®, budesonide pmdi, the combination of formoterol turbuhaler® and budesonide pmdi, and placebo in copd patients

Conditions: Chronic Obstructive Pulmonary Disease

Summary: the purpose of this study is to compare a combination asthma drug (symbicort) with its two components, budesonide and formoterol, taken individually or in combination, and with placebo in the long-term maintenance treatment of patients with chronic obstructive pulmonary disease (copd)


Eligibility criteria:
inclusion criteria: * a clinical diagnosis of copd with symptoms for more than 2 years * smoking history of 10 or more pack years * a history of at least one copd exacerbation requiring a course of oral steroids and/or antibiotics within 1-12 months before first visit. exclusion criteria: * a history of asthma * patients taking oral steroids. * any significant disease or disorder that may jeopardize the safety of the patient
deployment and clinical evaluation of an ai-powered digital oncology biomarker tool to guide treatment in tnbc

Conditions: Triple Negative Breast Cancer

Summary: tils have been shown to be predictive for response to neo-adjuvant chemotherapy in patients with tnbc in multiple studies (level-1b evidence for clinical validity as per remark criteria). tnbc patients with excellent survival outcome and low incidence of metastasis can be identified using a manual til score. furthermore, a fully end-to-end blinded evaluation of the same algorithm to be used in this study achieved \>90% accuracy for predicting disease free survival (dfs) and overall survival (os) in the pooled analysis of seven adjuvant phase-iii tnbc trials.


Eligibility criteria:
inclusion criteria: * age ≥18 years * confirmed diagnosis of triple negative breast cancer (non-metastatic) * planned for neo-adjuvant systemic therapy * written consent to generic tissue for research donation exclusion criteria: * patients declined consent for generic tissue for research donation
micrornas and prognosis in breast cancer

Conditions: Breast Cancer Female; Metastases Breast

Summary: mono-centric, observational retrospective and prospective study, designed for breast cancer patients to identify novel mirna based biomarker able to predict metastases development in breast cancer patients.

the potential role of mirnas will be studied as a predictor of metastases development. mirnas expression and mirnas promoter methylation will be evaluated in surgically removed specimens obtained from breast cancer patients at diagnosis. relevant mirnas will be first identified by analysing a retrospective breast cancer cohort including at least and subsequently validated on a prospective cohort.

Eligibility criteria:
retrospective cohort inclusion criteria: tissue samples from breast cancer cases diagnosed from 2004 to 2014 for which informed consent for tumour banking and complete clinicopathological and follow up data were available. exclusion criteria: pre-surgery neoadjuvant treatment for breast cancer with chemotherapy, lapatinib, trastuzumab, letrozole, anastrozole, exemestane or tamoxifen. other cancers diagnosed in the last five years. prospective cohort: inclusion criteria: ability to provide written informed consent; age greater than 18 years; histological diagnosis of breast disease; first diagnosis of breast cancer; syncronous distant metastasis absent. exclusion criteria: stage iv breast cancer; pre-surgery neoadjuvant treatment for breast cancer with chemotherapy, lapatinib, trastuzumab, letrozole, anastrozole, exemestane or tamoxifen; other cancers diagnosed in the last five years; alteration of mental status, dementia, or any psychiatric condition that might impair the ability to consciously sign the informed consent.

Keywords: microrna prognosis risk prediction
24-week water aerobics program for adults and older adults at different intensity levels

Conditions: Healthy

Summary: this goal of this clinical trial is to verify the best way to do water aerobics with adults and older adults. it wants to answer these questions: * is high-intensity water aerobics better than water aerobics performed at moderate intensity? * does a 24-week water aerobics program improve muscle strength, body weight, fat mass, triglycerides, cholesterol, blood pressure, and quality of life for adults and older adults? participants must: * do water aerobics at high or moderate intensity, twice a week for 45 minutes per class, for 24 weeks. * be assessed before starting the water aerobics program and after it ends to see if there are gains in muscle strength, body weight, fat mass, triglycerides, cholesterol, blood pressure, and quality of life. it was believed that all variables would get better after doing water aerobics, no matter the intensity. it was also expected that doing higher-intensity water aerobics would lead to larger gains in all measurements compared to moderate-intensity.


Eligibility criteria:
inclusion criteria: * at least 18 years of age exclusion criteria: * taking part in another physical exercise program * being recently hospitalized * having severe motor or cognitive problems * having any medical restrictions on physical exercise

Keywords: aquatic exercise intensity physical fitness health-related quality of life
analysis of intestinal microbiota as a predictor of response to treatment of spondyloarthritis with biotherapy

Conditions: Spondyloarthritis

Summary: spondyloarthritis (spa) is a group of inflammatory rheumatic disorders that mainly manifested by inflammatory pain of the spine, pelvis and sometimes limbs. classically, spa has been classified into several subtypes, such as ankylosing spondylitis (as), psoriatic arthritis (psa), inflammatory bowel disease (ibd)-associated. several studies have shown specific changes in the gut microbiota during spa. a recent, uncontrolled study suggested that the therapeutic response to anti-tnfα (tumor necrosis factor) therapy could be predicted by analysis of the gut microbiota. the purpose of the study medibiote 3 is to confirm that in spa, the composition of the intestinal microbiota at the initiation of treatment is predictive of the response to treatment with biotherapy (anti-tnfα / anti-il17).


Eligibility criteria:
inclusion criteria: for patient with spondyloarthritis: * diagnosed for spondyloarthritis or pure axial or axial type psoriatic rheumatism according to assessment of spondyloarthritis international society (asas) criteria. * requiring treatment with anti-tnfα or anti- il-17 according to the treatment recommendations of the french society of rheumatology (sfr) * patient not previously treated with biotherapy * aged ≥ 18 years * having given free and informed written consent * being affiliated to the center national security system social for control subject: * healthy volunteers without diagnosis of spondyloarthritis or any other chronic disease. * aged ≥ 18 years * having given free and informed written consent * being affiliated with or benefiting from a social security scheme. exclusion criteria: * persons treated with antibiotics, probiotics, prebiotics or any other treatment that may disrupt the gut microbiota within one month before stool sampling. * association with another chronic pathology